

Junning Cao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3902379/publications.pdf>

Version: 2024-02-01

29
papers

336
citations

1307594

7
h-index

839539

18
g-index

29
all docs

29
docs citations

29
times ranked

577
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 1897-1908.	4.2	12
2	Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. <i>BMC Cancer</i> , 2022, 22, 403.	2.6	1
3	Interim PET/CT result is the sole prognostic factor of survival in patients with advanced-stage diffuse large B-cell lymphoma: a subset analysis of a prospective trial. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2021, 327, 353-358.	1.5	0
4	Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma. <i>Annals of Nuclear Medicine</i> , 2021, 35, 834-842.	2.2	8
5	Phase II study of sequential chemoradiotherapy with L-asparaginase, dexamethasone, ifosfamide, cisplatin, and etoposide (DICE-L) in the early stage of extranodal natural killer (NK)/T-cell lymphoma. <i>Annals of Translational Medicine</i> , 2021, 9, 1178-1178.	1.7	3
6	Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	1.3	4
7	Camrelizumab for relapsed or refractory classical Hodgkin lymphoma: extended follow-up of the multicenter, single-arm, phase 2 study. <i>International Journal of Cancer</i> , 2021, .	5.1	11
8	The adhesion molecule ICAM-1 in diffuse large B-cell lymphoma post-rituximab era: relationship with prognostic importance and rituximab resistance. <i>Aging</i> , 2021, 13, 181-193.	3.1	6
9	Soluble ICAM-1 As Effective Serologic Marker to Predict Clinical Outcome for Early -Stage I/II Nasal Natural Killer /T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 4542-4542.	1.4	0
10	Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 616-626.	2.2	10
11	PDGFD induces ibrutinib resistance of diffuse large B-cell lymphoma through activation of EGFR. <i>Molecular Medicine Reports</i> , 2020, 21, 2209-2219.	2.4	7
12	Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIe, extranodal NK/T-cell lymphoma patients. <i>Cancer Medicine</i> , 2020, 9, 5400-5405.	2.8	6
13	Switching Fractioned R-CHOP Cycles to Standard R-CHOP Cycles Guided by Endoscopic Ultrasonography in Treating Patients with Primary Gastric Diffuse Large B-Cell Lymphoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 5041-5048.	1.9	3
14	Inhibitor of DNA Binding 3 Is a Potential Prognostic Biomarker in Non-GCB Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 14-15.	1.4	0
15	Results from a Phase 1 Dose Escalation Study of HMPL-689, a Selective Oral Phosphoinositide 3-Kinase-Delta Inhibitor, in Chinese Patients with Relapsed/Refractory (R/R) Lymphomas. <i>Blood</i> , 2020, 136, 38-38.	1.4	1
16	A Single-Arm, Multicenter, Phase II Study of Camrelizumab in Relapsed or Refractory Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2019, 25, 7363-7369.	7.0	102
17	Hexokinase II Expression As a Prognosis Marker in Diffuse Large B-Cell Lymphoma (DLBCL) Pre- and Post-the Incorporation of Rituximab to Standard CHOP Chemotherapy. <i>Blood</i> , 2019, 134, 5233-5233.	1.4	0
18	Role of radiotherapy in patients with limited diffuse large B-cell lymphoma of Waldeyer's ring in remission after R-CHOP immunochemotherapy. <i>Leukemia Research</i> , 2018, 74, 80-85.	0.8	2

#	ARTICLE	IF	CITATIONS
19	A phase I dose escalation study of hPV19, a novel humanized monoclonal antibody against vascular endothelial growth factor (VEGF), in patients with advanced solid tumors refractory to standard therapy.. Journal of Clinical Oncology, 2018, 36, 2522-2522.	1.6	0
20	Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma. OncoTargets and Therapy, 2017, Volume 10, 145-151.	2.0	4
21	A retrospective analysis of outcomes for primary mediastinal large B-cell lymphoma treated with RCHOP followed by radiotherapy or front-line autologous stem cell transplantation. Hematology, 2017, 22, 258-264.	1.5	8
22	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. Journal of Hematology and Oncology, 2017, 10, 22.	17.0	50
23	Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors. Oncologist, 2017, 22, 638-e56.	3.7	3
24	Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget, 2016, 7, 32519-32531.	1.8	14
25	A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2016, 78, 259-269.	2.3	45
26	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. Oncotarget, 2016, 7, 33331-33339.	1.8	6
27	A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors. Journal of Hematology and Oncology, 2014, 7, 22.	17.0	29
28	Epirubicin Does Not Lower The Risk Of Cardiac Toxicity Than Doxorubicin In Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma Grade 3 (FLG3): Results From a 398-Case Prospective Randomized Phase III Clinical Trial (NCT00854568). Blood, 2013, 122, 372-372.	1.4	1
29	Re-Assessment of the Prognostic Value of International Prognostic Index (IPI) and Revised IPI (R-IPI) in Patients with Diffuse Large B-Cell Lymphoma Treated with or without Rituximab in Chinese Populations: A Retrospective Multicenter Study by Shanghai Lymphoma Research Group. Blood, 2011, 118, 2649-2649.	1.4	0